PR Newswire
LAS VEGAS, March 11, 2026
The bipolar depression market is anticipated to increase during the forecast period (2026-2036), owing to the rise in the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others and healthcare spending across the 7MM, reports DelveInsight.
LAS VEGAS, March 11, 2026 /PRNewswire/ — Recently published Bipolar Depression Market Insights report includes a comprehensive understanding of current treatment practices, bipolar depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Bipolar Depression Market Summary
- The total bipolar depression treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounted for the largest bipolar depression treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Bipolar depression has the highest prevalence among diagnosed cases in the US within the 18-25 age group, affecting approximately 3.40% of this population.
- Leading bipolar depression companies, such as Xenon Pharmaceuticals, Autobahn Therapeutics, AbbVie, Alto Neuroscience, NRx Pharmaceuticals, LB Pharmaceuticals, and others, are developing new bipolar depression treatment drugs that can be available in the bipolar depression market in the coming years.
- The promising bipolar depression therapies in clinical trials include Azetukalner, Elunetirom (ABX-002), ABBV-932, ALTO-100, NRX-101, LB-102, Icalcaprant (ABBV-1354), and others.
Discover what is the CAGR for bipolar depression therapeutics market @ https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Bipolar Depression Market
- Rising Bipolar Depression Prevalence: According to DelveInsight’s estimates, the diagnosed prevalent cases of bipolar depression are expected to increase during the forecast period due to improved diagnostic tools, genetic predisposition research, and stress-related lifestyle changes contributing.
- Technological & Diagnostic Innovations: Advances in diagnostic tools, including imaging, biomarkers, and digital mood tracking tools, enhance early detection and personalized treatment planning.
- Launch of Emerging Drugs: The dynamics of the bipolar depression market are expected to change in the coming years owing to the launch of emerging therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others.
Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that despite advancements, bipolar depression continues to be difficult to treat, with many patients experiencing relapse or inadequate symptom control. Emerging therapies targeting novel pathways, including dopamine and glutamate modulation, offer hope for more effective, personalized treatments.
Bipolar Depression Market Analysis
- The pharmacological treatment of bipolar depression primarily involves mood stabilizers like lithium and valproate, along with atypical antipsychotics such as quetiapine, lurasidone, and the olanzapine/fluoxetine combination.
- The growing demand for these medications is driven by their effectiveness in managing depressive episodes and preventing relapse.
- Newer-generation antipsychotics with improved safety profiles and fewer side effects are gaining market traction.
- Approved treatments for bipolar depression include FANAPT, marketed by Vanda Pharmaceuticals, and VRAYLAR, marketed by AbbVie, among others.
- Despite available options, substantial unmet needs persist due to suboptimal response, delayed diagnosis, and poor long-term adherence.
- Current therapies present safety concerns, including metabolic and cognitive side effects.
- Innovative therapies such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others are in development and may offer new future treatment options.
Bipolar Depression Competitive Landscape
Some of the bipolar depression drugs under development include Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others.
Xenon Pharmaceuticals’ Azetukalner is an experimental oral modulator of Kv7 potassium channels being evaluated for bipolar depression. Its goal is to stabilize excessive neuronal activity and ease depressive symptoms without causing mania or the common side effects associated with antipsychotic medications.
Autobahn Therapeutics’ ABX-002 is an orally administered, brain-targeted thyroid hormone beta receptor (TRβ) agonist intended to act specifically within neural regions linked to depression. It demonstrates strong therapeutic potential while limiting the peripheral adverse effects typically seen with synthetic thyroid hormones. This novel strategy may offer a safer, more effective treatment avenue for mood disorders, improving outcomes with fewer systemic risks.
AbbVie’s ABBV-932 is a selective modulator of the D3 dopamine receptor that is being developed as a standalone therapy for bipolar disorder and generalized anxiety disorder. In partnership with Gedeon Richter, the program focuses on fine-tuning dopamine circuits related to mood and anxiety. By specifically targeting D3 receptors, ABBV-932 aims to deliver a more precise therapeutic option that could enhance symptom management while reducing side effects compared to current treatments.
Alto Neuroscience’s ALTO-100 is a first-of-its-kind oral small molecule thought to enhance neuroplasticity within the hippocampus, an area of the brain essential for both mood regulation and cognition. It is based on the long-held theory that reduced hippocampal neuroplasticity contributes to depression and is therefore intended for patients whose cognitive patterns suggest such a deficit. ALTO-100 is currently in Phase 2b trials as an adjunctive therapy for bipolar depression.
NRx Pharmaceuticals’ NRX-101 is a proprietary oral combination of two FDA-approved medications: D-cycloserine, which acts as an NMDA receptor modulator at certain doses, and lurasidone, a 5-HT2A receptor blocker. If cleared by the U.S. FDA and other regulators, it would represent the first treatment regimen specifically designed for severe bipolar depression in patients experiencing acute or sub-acute suicidal thoughts or behaviors (ASIB & SSIB).
The anticipated launch of these emerging therapies are poised to transform the bipolar depression market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the bipolar depression market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about emerging bipolar depression therapies in clinical trials @ Bipolar Depression Drugs
Recent Developments in the Bipolar Depression Market
- In January 2026, Autobahn Therapeutics reported that topline results from the Phase II AMPLIFY-BD trial evaluating adjunctive azetukalner in bipolar depression are expected in the second quarter of 2026.
- In January 2026, JP Morgan Healthcare Conference reported that the Phase III X-CEED study evaluating azetukalner in patients with bipolar depression I or II is underway.
What is Bipolar Depression?
Bipolar depression is the depressive phase of bipolar disorder, a mood disorder characterized by extreme shifts in energy, activity, and emotions. During depressive episodes, a person may experience deep sadness, hopelessness, low motivation, sleep changes, and difficulty concentrating. Unlike ordinary depression, bipolar depression occurs as part of a cycle that also includes episodes of mania or hypomania, where mood and energy levels are unusually elevated. Understanding bipolar depression is important because its symptoms, causes, and treatment approaches can differ from other forms of depression, and effective management often requires a combination of medication, therapy, and lifestyle support.
Bipolar Depression Epidemiology Segmentation
The bipolar depression epidemiology section provides insights into the historical and current bipolar depression patient pool and forecasted trends for the leading markets. The prevalence of bipolar depression in the UK, Germany, and Italy is approximately 1%, highlighting the disorder’s significant presence across different populations in Europe.
The bipolar depression treatment market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:
- Diagnosed Prevalent Cases of Bipolar Depression
- Type-specific Diagnosed Prevalent Cases of Bipolar Depression
- Severity-specific Diagnosed Prevalent Cases of Bipolar Depression
- Age-specific Diagnosed Prevalent Cases of Bipolar Depression
Bipolar Depression Market Report Metrics
Details
Study Period
2022-2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Bipolar Depression Epidemiology Segmentation Diagnosed Prevalent Cases of Bipolar Depression, Type-specific Diagnosed Prevalent Cases of Bipolar Depression,
Severity-specific Diagnosed Prevalent Cases of Bipolar Depression, and Age-specific Diagnosed Prevalent Cases of
Bipolar Depression
Key Bipolar Depression Companies Xenon Pharmaceuticals, Autobahn Therapeutics, AbbVie, Alto Neuroscience, NRx Pharmaceuticals, LB Pharmaceuticals, Vanda
Pharmaceuticals, and others
Key Bipolar Depression Therapies Azetukalner, Elunetirom (ABX-002), ABBV-932, ALTO-100, NRX-101, LB-102, Icalcaprant (ABBV-1354), VRAYLAR, FANAPT,
and others
Scope of the
Bipolar Depression
Market Report
- Therapeutic Assessment: Bipolar Depression current marketed and emerging therapies
- Bipolar Depression Market Dynamics: Key Market Forecast Assumptions of Emerging Bipolar Depression Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Bipolar Depression Market Access and Reimbursement
Download the report to understand antipsychotics vs antidepressants in bipolar depression @ Bipolar Depression Market Analysis
Table of Contents
1
Bipolar Depression Market Key Insights
2
Bipolar Depression Market Report Introduction
3
Bipolar Depression Market Overview
3.1 Market Share (%) Distribution of Bipolar Depression by Therapies in
the 7MM in 2025
3.2 Market Share (%) Distribution of Bipolar Depression by Therapies in
the 7MM in 2036
4
Methodology of Epidemiology and Market
5
Executive Summary
6
Key Events
7
Disease Background and Overview
7.1
Introduction
7.2
Causes
7.3
Pathophysiology
7.4
Symptoms
7.5
Diagnosis
7.6
Treatment and Management of Bipolar Depression
8
Epidemiology and Patient Cases
8.1
Key Findings
8.2
Assumptions and Rationale: The 7MM
8.3 Diagnosed Prevalent Cases of Bipolar Depression in the 7MM
8.4
The US
8.4.1
Diagnosed Prevalent Cases of Bipolar Depression
8.4.2 Type-specific Diagnosed Prevalent Cases of Bipolar Depression
8.4.3 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression
8.4.4 Age-specific Diagnosed Prevalent Cases of Bipolar Depression
8.5
EU4 and the UK
8.6
Japan
9
Bipolar Depression Patient Journey
10
Marketed Bipolar Depression Therapies
10.1
Key Cross Competition
10.2
VRAYLAR (Cariprazine): AbbVie
10.2.1
Product Description
10.2.2
Regulatory Milestone
10.2.3
Other Developmental Activities
10.2.4
Clinical Trials Information
10.2.5
Safety and Efficacy
10.3
FANAPT (Iloperidone): Vanda Pharmaceuticals
List to be continued in the report…
11
Emerging Bipolar Depression Therapies
11.1
Key Cross Competition
11.2
Azetukalner: Xenon Pharmaceuticals
11.2.1
Drug Description
11.2.2
Other Developmental Activities
11.2.3
Clinical Trials Information
11.2.4
Safety and Efficacy
11.2.5
Analyst Views
11.3
Elunetirom: Autobahn Therapeutics
11.4
ABBV-932: AbbVie
List to be continued in the report…
12
Bipolar Depression: Market Analysis
12.1
Key Findings
12.2
Key Bipolar Depression Market Forecast Assumptions
12.3
Attribute Analysis
12.4
Bipolar Depression Market Outlook
12.5
Total Market Size of Bipolar Depression in the 7MM
12.6
Market Size of Bipolar Depression by Therapies in the 7MM
12.7
The US Bipolar Depression Market
12.7.1
Total Market Size of Bipolar Depression
12.7.2
Market size of Bipolar Depression by Therapies
12.8
EU4 and the UK Bipolar Depression Market
12.9
Japan Bipolar Depression Market
13
Key Opinion Leaders’ Views on Bipolar Depression
14
Bipolar Depression Market SWOT Analysis
15
Bipolar Depression Market Unmet needs
16
Bipolar Depression Market Access and Reimbursement
16.1
The US
16.2
In EU4 and the UK
16.3
Japan
17
Bibliography
18
Acronyms and Abbreviations
19
Bipolar Depression Market Report Methodology
Related Reports
Bipolar Depression Clinical Trial Analysis
Bipolar Depression
Pipeline Insight
–
2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key bipolar depression companies, including NRx Pharmaceuticals, Inc., Autobahn Therapeutics, Sunovion Pharmaceuticals Inc., and others.
Generalized Anxiety Disorder
Market
Generalized Anxiety Disorder
Market Insights, Epidemiology, and Market Forecast
–
2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key generalized anxiety disorder companies including VistaGen Therapeutics, MindMed, Sumitomo Pharma America, Inc., Otsuka Pharmaceutical Co., Ltd, Sunovion Pharmaceuticals Inc., Cybin IRL Limited, Engrail Therapeutics INC., Bionomics Limited, Receptor Life Sciences, MannKind Corporation, and others.
Schizophrenia
Market
Schizophrenia
Market Insights, Epidemiology, and Market Forecast
–
2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key schizophrenia companies including Boehringer Ingelheim, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Karuna Therapeutics, Bristol Myers Squibb, Royalty Pharma, Acadia Pharmaceuticals, Rovi Pharmaceuticals Laboratories (Laboratorios Farmacéuticos Rovi), Teva Pharmaceutical, MedinCell, Lyndra Therapeutics, Neurocrine Biosciences, Mitsubishi Tanabe Pharma, Luye Pharma, Newron Pharmaceuticals, and others.
Social Anxiety Disorder
Market
Social Anxiety Disorder
Market Insights, Epidemiology, and Market Forecast
–
2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key social anxiety disorder companies including Mochida Pharmaceutical, Lundbeck, Vistagen Therapeutics, Bionomics, EmpowerPharm, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur [email protected] +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bipolar-depression-market-expected-to-witness-accelerated-expansion-during-the-forecast-period-20262036-amid-advancements-in-psychiatric-therapies–delveinsight-302710471.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…